Measurement of amino-terminal propeptide of C-type natriuretic peptide in patients with idiopathic short stature or isolated growth hormone deficiency
Authors:
- Xiao YuanXYXiao Yuan
- Dong ZhiyaDZDong Zhiya
- Lu WenliLWLu Wenli
- Wang XiumingWXWang Xiuming
- Sun WenxinSWSun Wenxin
- Wang DefenWDWang Defen
- Ni JihongNJNi Jihong
- Chen FengshengCFChen Fengsheng
- Wang JunqiWJWang Junqi
- Wang WeiWWWang Wei
- 1 January 2011
- journal article
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 24 (11-12) , 989-94
Abstract
To explore the value of amino-terminal propeptide of C-type natriuretic peptide (NTproCNP) in evaluating the effectiveness of therapy with recombinant human growth hormone (rhGH) in patients with idiopathic short stature (ISS) and isolated growth hormone deficiency (IGHD). Forty-eight prepubertal children (IGHD = 25, ISS = 23) treated for at least 1 year with rhGH were included. Insulin growth factor-1 (IGF-I) and NTproCNP serum levels were measured before starting treatment and again 6 months later. Twelve months after starting treatment, all patients were assessed and annual growth velocity (GV), height standard deviation score (HTSDS), and gain HTSDS (deltaHTSDS) were recorded. In the GHD group, positive relationships between GV and change of IGF-I(SDS) (deltaIGF-I(SDS)), GV and change of NTproCNP concentrations (deltaNTproCNP) were found. GH peak value was also positively associated with IGF-I(SDS) and NTproCNP before therapy and deltaIGF-I(SDS) and deltaNTproCNP were positively associated. In the ISS group, GV was associated with only deltaNTproCNP. NTproCNP is a novel biomarker of growth as levels increase during growth-promoting treatment. Furthermore, IGF-I is also valuable in evaluating the efficacy of rhGH therapy in short stature patients.Keywords
This publication has 21 references indexed in Scilit:
- Response of plasma CNP forms to acute anabolic and catabolic interventions in growing lambsAmerican Journal of Physiology-Endocrinology and Metabolism, 2007
- C-type natriuretic peptide in growth: A new paradigmGrowth Hormone & IGF Research, 2006
- Amino-Terminal proCNP: A Putative Marker of Cartilage Activity in Postnatal GrowthPediatric Research, 2005
- Complementary antagonistic actions between C-type natriuretic peptide and the MAPK pathway through FGFR-3 in ATDC5 cellsBone, 2005
- Mutations in the Transmembrane Natriuretic Peptide Receptor NPR-B Impair Skeletal Growth and Cause Acromesomelic Dysplasia, Type MaroteauxThe American Journal of Human Genetics, 2004
- Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathwayNature Medicine, 2003
- Furin-mediated Processing of Pro-C-type Natriuretic PeptideJournal of Biological Chemistry, 2003
- C-type natriuretic peptide/guanylate cyclase B system in ATDC5 cells, a chondrogenic cell lineJournal of Bone and Mineral Metabolism, 2002
- Consensus Guidelines for the Diagnosis and Treatment of Growth Hormone (GH) Deficiency in Childhood and Adolescence: Summary Statement of the GH Research SocietyThe Journal of Clinical Endocrinology & Metabolism, 2000
- C-Type natriuretic peptide (CNP): A new member of natriuretic peptide family identified in porcine brainBiochemical and Biophysical Research Communications, 1990